Charles River Laboratories International
13
25M
8
0.17
1
0.38
1
- Areas of investment
Summary
In 1947 was created Charles River Laboratories International, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Wilmington. The company was established in North America in United States.
The typical case for the fund is to invest in rounds with 7 participants. Despite the Charles River Laboratories International, startups are often financed by Kurma Partners, Idinvest Partners, Aurinvest. The meaningful sponsors for the fund in investment in the same round are investiere | Verve Capital Partners, Strategic Partners, Norgine Ventures.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - France. Among the most successful fund investment fields, there are Biotechnology, Therapeutics. Among the various public portfolio startups of the fund, we may underline PathoQuest
The usual things for fund are deals in the range of 5 - 10 millions dollars. The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2019.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 13
- Lead investments
- 1
- Exits
- 1
- Rounds per year
- 0.17
- Follow on index
- 0.38
- Investments by industry
- Biotechnology (7)
- Health Care (4)
- Therapeutics (4)
- Life Science (3)
- Medical (1) Show 2 more
- Investments by region
-
- United States (7)
- France (3)
- Canada (2)
- Ireland (1)
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 26M
- Group Appearance index
- 1.00
- Avg. company exit year
- 13
- Avg. multiplicator
- 12.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Ability biologics | 18 Jun 2024 | Biotechnology, Life Science | Seed | 6M | Quebec, Quebec, Canada |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.